for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BioMarin Pharmaceutical Inc.

BMRN.O

Latest Trade

89.66USD

Change

-0.21(-0.23%)

Volume

764,152

Today's Range

88.38

 - 

89.94

52 Week Range

62.88

 - 

96.20

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
89.87
Open
89.81
Volume
764,152
3M AVG Volume
25.02
Today's High
89.94
Today's Low
88.38
52 Week High
96.20
52 Week Low
62.88
Shares Out (MIL)
179.63
Market Cap (MIL)
15,975.87
Forward P/E
--
Dividend (Yield %)
--

Next Event

Biomarin Pharmaceutical Inc at Leerink Global Healthcare Conference

Latest Developments

More

Biomarin Says Dan Spiegelman Steps Down As Cfo

Invitae - Behind The Seizure Program Expands Access To Genetic Testing For Children

Biomarin Submits Biologics License Application To U.S. FDA For Valoctocogene Roxaparvovec To Treat Hemophilia A

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company's therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A). The Company is conducting clinical trials on various product candidates for the treatment of various diseases. Its clinical product candidates include Brineura, pegvaliase, vosoritide, BMN 270 and BMN 250.

Contact Info

105 Digital Dr

+1.415.5066700

http://www.bmrn.com/

Executive Leadership

Jean-Jacques Bienaime

Chairman of the Board, Chief Executive Officer

Brian R. Mueller

Acting Chief Financial Officer, Senior Vice President, Chief Accounting Officer

Henry J. Fuchs

President - Worldwide Research & Development

G. Eric Davis

Executive Vice President, General Counsel, Secretary

Jeff Robert Ajer

Executive Vice President, Chief Commercial Officer

Key Stats

1.84 mean rating - 25 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

1.1K

2017

1.3K

2018

1.5K

2019(E)

1.7K
EPS (USD)

2016

-3.810

2017

-0.670

2018

-0.440

2019(E)

-0.293
Price To Earnings (TTM)
--
Price To Sales (TTM)
9.97
Price To Book (MRQ)
5.20
Price To Cash Flow (TTM)
251.96
Total Debt To Equity (MRQ)
27.85
LT Debt To Equity (MRQ)
27.75
Return on Investment (TTM)
-1.07
Return on Equity (TTM)
-0.92

Latest News

Latest News

BRIEF-Biomarin's Biologics License Application For Valoctocogene Roxaparvovec Accepted For Priority Review By FDA With Review Action Date Of August 21, 2020

* BIOMARIN'S BIOLOGICS LICENSE APPLICATION FOR VALOCTOCOGENE ROXAPARVOVEC ACCEPTED FOR PRIORITY REVIEW BY FDA WITH REVIEW ACTION DATE OF AUGUST 21, 2020 Source text for Eikon: Further company coverage:

CORRECTED-BRIEF-Biomarin Pharmaceutical Reports Qtrly Earnings Per Share Of $0.30 (Oct.23)

* Q3 REVENUE $461.1 MILLION VERSUS REFINITIV IBES ESTIMATE OF $454.5 MILLION

BioMarin says data shows hemophilia gene therapy effects could wane

BioMarin Pharmaceutical Inc said on Tuesday early trial data for its gene therapy for hemophilia A suggested the one-time infusion's effect on some patients' bleeding disorders would last eight years.

BRIEF-BioMarin Says Payers Unlikely To Accept Price Equivalent To Over 5 Years Of Standard Treatment Costs For Hemophilia Gene Therapy

* BIOMARIN CEO SAYS BELIEVES ONCE HEMOPHILIA GENE THERAPY IS APPROVED CO WILL BE IN 'PRETTY GOOD SHAPE' FOR DISCUSSION ON PRICE WITH PAYERS BASED ON FIVE YEARS OF COSTS, SIMILAR TO NOVARTIS

BioMarin sets stage early for hemophilia cure off-Broadway

(This version of the November 21st story has been refiled to show in paragraph 23 that Sangamo Therapeutics has six people in clinical trials)

FDA approves BioMarin rare metabolic disorder drug, shares rise

U.S. regulators on Thursday approved BioMarin Pharmaceutical Inc's Palynziq for adults with phenylketonuria, a rare metabolic disorder, sending shares of the biotechnology company up 3 percent after hours.

BRIEF-Biomarin Pharmaceutical Q1 GAAP Loss Per Share $0.26

* Q1 REVENUE $373.4 MILLION VERSUS I/B/E/S VIEW $348.7 MILLION

BRIEF-Biomarin Pharmaceutical Reports Q1 Loss Per Share Of $0.25

* Q1 REVENUE $373.4 MILLION VERSUS I/B/E/S VIEW $348.7 MILLION

BRIEF-Biomarin Pharma CEO's 2017 Compensation Was $15.9 Million

* BIOMARIN PHARMACEUTICAL INC SAYS CEO JEAN-JACQUES BIENAIMÉ'S 2017 TOTAL COMPENSATION WAS $15.9 MILLION VERSUS $16.9 MILLION IN 2016 – SEC FILING

BRIEF-European Medicines Agency Accepts Biomarin's Marketing Application For Pegvaliase

* EUROPEAN MEDICINES AGENCY (EMA) ACCEPTS BIOMARIN'S MARKETING APPLICATION FOR PEGVALIASE MAA FOR TREATMENT OF PHENYLKETONURIA (PKU)

BRIEF-BioMarin Q4 GAAP Loss Per Share $0.30

* BIOMARIN ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Biomarin Receives Anticipated Notification Of PDUFA Extension For Pegvaliase Biologics License Application

* BIOMARIN RECEIVES ANTICIPATED NOTIFICATION OF PDUFA EXTENSION FOR PEGVALIASE BIOLOGICS LICENSE APPLICATION (BLA) TO MAY 28, 2018

BRIEF-Biomarin Doses First Patient In Late-Stage Trial Of Gene Therapy For Bleeding Disorder

* BIOMARIN DOSES FIRST PATIENT IN GLOBAL GENER8-1 PHASE 3 STUDY OF VALOCTOCOGENE ROXAPARVOVEC GENE THERAPY FOR SEVERE HEMOPHILIA A Source text for Eikon: Further company coverage:

BRIEF-Biomarin Sells Second Priority Review Voucher For $125 Mln

* BIOMARIN SELLS SECOND PRIORITY REVIEW VOUCHER FOR $125 MILLION

BRIEF-Biomarin reports Q3 loss $0.07/shr

* Q3 earnings per share view $-0.14 -- Thomson Reuters I/B/E/S

BRIEF-FDA grants Breakthrough Therapy Designation for BioMarin's gene therapy for hemophilia A

* FDA grants Breakthrough Therapy Designation for BioMarin's valoctocogene roxaparvovec (formerly BMN 270), an investigational gene therapy for hemophilia A

BRIEF-Biomarin Pharmaceutical: Increased board size from nine to ten members​

* Biomarin Pharmaceutical says on September 28, 2017, board of directors of increased size of board from nine to ten members - SEC filing Source: (http://bit.ly/2yWOHiP) Further company coverage:

BRIEF-FDA not planning to hold advisory committee meeting for Biomarin's Pegvaliase BLA

* FDA not currently planning to hold advisory committee meeting for Biomarin's Pegvaliase Biologics License Application (BLA)

BRIEF-FDA accepts Biomarin's Pegvaliase Biologics License Application

* FDA accepts Biomarin's Pegvaliase Biologics License Application (bla) and grants priority review designation

BRIEF-BioMarin announces offering of $450 mln of 0.599 pct senior convertible notes

* BioMarin announces offering of $450 million of 0.599% senior subordinated convertible notes due 2024

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up